Quick Answer
Eledon Pharmaceuticals, Inc. reported Stockholders Equity of $81.09 million for the year ending 2025.
- Eledon Pharmaceuticals, Inc. showed an increase of +29.8% in Stockholders Equity from 2024 to 2025.
- This data is from Eledon Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: $101.61 million | Q1 2015: $90.90 million | Q2 2015: $82.75 million | Q3 2015: $71.90 million | Q1 2016: $51.41 million | Q2 2016: $38.88 million | Q3 2016: $30.26 million | Q1 2017: $23.36 million | Q2 2017: $23.44 million | Q3 2017: $20.62 million | Q1 2018: $24.30 million | Q2 2018: $21.51 million | Q3 2018: $18.33 million | Q1 2019: $9.93 million | Q2 2019: $16.03 million | Q3 2019: $13.37 million | Q1 2020: $11.75 million | Q2 2020: $9.36 million | Q3 2020: $21.51 million | Q1 2021: $183.87 million | Q2 2021: $178.52 million | Q3 2021: $170.75 million | Q1 2022: $156.32 million | Q2 2022: $149.38 million | Q3 2022: $141.09 million | Q1 2023: $74.79 million | Q2 2023: $43.77 million | Q3 2023: $35.60 million | Q1 2024: -$70.42 million | Q2 2024: -$64.20 million | Q3 2024: $20.36 million | Q1 2025: $58.89 million | Q2 2025: $50.33 million | Q3 2025: $35.36 million.
- Over the full 15 years of available data (2011 to 2025), Eledon Pharmaceuticals, Inc.'s Stockholders Equity has grown by 366.4%.
- Historical annual values: Fiscal year 2025: $81.09 million | Fiscal year 2024: $62.45 million | Fiscal year 2023: -$48.49 million | Fiscal year 2022: $84.18 million | Fiscal year 2021: $164.00 million | Fiscal year 2020: $190.60 million | Fiscal year 2019: $9.47 million | Fiscal year 2018: $14.49 million | Fiscal year 2017: $19.45 million | Fiscal year 2016: -$2.70 million | Fiscal year 2015: $2.78 million | Fiscal year 2014: $103.50 million | Fiscal year 2013: -$55.27 million | Fiscal year 2012: -$39.90 million | Fiscal year 2011: -$30.43 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: